Heading into Wednesday, September 2, 2026, U.S. markets are digesting a rough start to the month — surging bond yields, renewed U.S.-Iran hostilities in the Strait of Hormuz, and a biotech blowup that erased $1.5 billion in a single session. But away from the mega-cap headlines, a genuinely diverse group of stocks under $3 is quietly building fresh catalysts of their own: crypto-treasury pivots, corporate name changes, and low-float names with tiny share counts that can move violently on modest volume. Here are 10 stocks under $3 to watch tomorrow, with full data and the honest risks behind each one.
Today’s Market Snapshot
- Dow Jones: -418.31 (-0.79%) to 52,767
- S&P 500: -54.56 (-0.71%) to 7,631
- Nasdaq Composite: -271.12 (-1.03%) to 26,099
- The backdrop: Oil tankers were struck in the Strait of Hormuz Monday night, triggering fresh U.S. strikes on Iranian targets and sending Brent crude up 4.6% to $94.65 a barrel — a risk-off tone that’s pushed the 10-year Treasury yield toward 4.8%.
- Why this matters for sub-$3 names: Rising rates make capital-raising more expensive across the board, but they also tend to divert speculative retail trading volume toward cheap, catalyst-driven small caps once large-cap volatility settles — a dynamic worth watching into Wednesday’s session.
1. Cemtrex, Inc. (CETX) — ~$2.70 | An Industrial Tech Turnaround Still Searching for Traction
| Metric | Value |
|---|---|
| Recent Price | ~$2.70 |
| Sector | Industrial technology, smart infrastructure, advanced security |
Cemtrex operates across industrial technology, smart infrastructure, and advanced security solutions, and has been trading far below its historical levels — a setup that appeals specifically to deep-value and turnaround traders looking for re-rating potential. The company hasn’t had a single dramatic catalyst recently; instead, it’s on trader watchlists as a name where any improvement in operating performance, contract wins, or balance-sheet progress could shift sentiment quickly given how depressed the current valuation is.
Bull Case vs. Bear Case
Bull case: In low-priced tech-industrial names like this, even modest execution gains often translate into outsized percentage stock moves — a normalization year where efficiency gains or revenue stabilization materialize could spark renewed market interest.
Bear case: With no single concrete catalyst currently in motion, CETX remains a “wait and see” story — the stock could just as easily continue drifting without a specific event to change the narrative.
Technical Levels and Forecast
| Level | Type | Note |
|---|---|---|
| $2.00 | Psychological support | Round-number floor |
| $2.70 (current) | Trading zone | Reference price |
| $3.00 | Near-term resistance | Round-number ceiling |
What to watch tomorrow: Any contract win or balance-sheet update announcement — this is a name that needs a specific catalyst to break out of its current range.
2. SurgePays, Inc. (SURG) — ~$2.70–$2.85 | A Fintech Betting on AI-Driven Subscriber Growth
| Metric | Value |
|---|---|
| Recent Price | ~$2.70–$2.85 |
| 52-Week Range | $1.05 – $3.47 |
| Analyst Target Range | $5.00–$9.50 (Buy/Strong Buy) |
SurgePays, a fintech and wireless distribution company serving the subprime mobile market, has been building momentum after revising a wireless deal in July and continuing to push its AI decisioning platform aimed at increasing revenue per subscriber. Revenue surged 292% year-over-year in a recent quarter to $18.7 million, with narrowing losses — a genuinely strong growth signal for a company still working through profitability.
Bull Case vs. Bear Case
Bull case: The average analyst target of $5.00-$9.50 implies substantial upside from current levels, reflecting confidence that the AI-driven subscriber growth model can keep compounding.
Bear case: Full-year 2025 revenue actually declined 6.44% even as more recent quarters have shown acceleration, and losses — while shrinking — remain steep at over $36 million, meaning the turnaround is real but not yet complete.
Technical Levels and Forecast
| Level | Type | Note |
|---|---|---|
| $1.05 | 52-week low | Absolute floor |
| $2.50 | Support zone | Recent consolidation base |
| $2.70–$2.85 (current) | Trading zone | Near-term action |
| $3.47 | 52-week high | Immediate resistance |
| $5.00–$9.50 | Analyst target range | Longer-term bull case |
What to watch tomorrow: Subscriber growth and margin trends in any forthcoming operational update — sustained momentum would be needed to justify closing the gap toward analyst targets.
3. Pineapple Financial Inc. (PAPL) — ~$0.91–$0.94 | A Mortgage Fintech Pivoting Into Injective Protocol
| Metric | Value |
|---|---|
| Recent Price | ~$0.91–$0.94 |
| Float | ~7.98 million shares |
| Available Capital Reserves | ~$20.79 million |
Pineapple Financial, a Canadian mortgage technology platform, has pivoted hard into a digital-asset treasury strategy in 2026, most recently disclosing the acquisition of 560,647 INJ tokens (Injective Protocol) as part of an ongoing crypto allocation. The company launched a share buyback program in April, with repurchases underway immediately after authorization, and Q2 2026 results showed a shift to positive adjusted operating income despite a headline net loss driven by non-cash digital-asset revaluation.
Bull Case vs. Bear Case
Bull case: With a float of only about 7.98 million shares, even modest buying pressure can move this stock meaningfully, and the crypto-treasury pivot gives shareholders indirect exposure to Injective Protocol’s price action alongside the core mortgage-tech business.
Bear case: The pivot means PAPL is increasingly correlated to crypto market sentiment rather than traditional mortgage-market fundamentals — a genuinely different risk profile than what the stock represented a year ago, and one that could work against holders if crypto sentiment sours.
Technical Levels and Forecast
| Level | Type | Note |
|---|---|---|
| $0.75 | Recent support zone | Prior consolidation base |
| $0.91–$0.94 (current) | Trading zone | Near-term action |
| $1.10 | Near-term resistance | Recent swing high |
What to watch tomorrow: Any further disclosed digital-asset purchases, and Injective Protocol’s own price action — both are now direct drivers of PAPL’s near-term trajectory.
4. Mainz Biomed / Quantum Cyber Corp (MYNZ) — ~$0.61–$0.84 | A Cancer-Diagnostics Company Reinventing Itself as a Quantum Cybersecurity Play
| Metric | Value |
|---|---|
| Recent Price | ~$0.61–$0.84 |
| Shares Outstanding | ~3.04 million |
| Market Cap | ~$5.7 million |
| Consensus Rating | Moderate Buy, $14.00 price target |
This is one of the more unusual corporate transformations on the market right now. Mainz Biomed, formerly a molecular genetics cancer-diagnostics company behind the ColoAlert colorectal cancer screening test, appointed Robert P. Liscouski — who brings government cybersecurity and quantum technology leadership experience — as Chairman, and announced plans to change its name to Quantum Cyber Corp under the new ticker QUCY. The company says it will continue developing its U.S. pancreatic cancer screening business while evaluating a sale of its colorectal cancer screening assets and winding down its German subsidiary entirely.
Bull Case vs. Bear Case
Bull case: With only about 3.04 million shares outstanding, this is one of the tightest floats on the list — any real news flow around the quantum-cybersecurity pivot could produce an outsized share-price reaction given how few shares are available to trade.
Bear case: Pivoting an entire company from cancer diagnostics to quantum cybersecurity is an enormous strategic gap to bridge, and the stock’s own 52-week range ($1.28 to $16.04 in one data set, with figures as low as $0.55 in another) reflects a name that’s already seen dramatic value destruction well before this latest transformation.
Technical Levels and Forecast
| Level | Type | Note |
|---|---|---|
| $0.55 | Recent low reference | Deep base |
| $0.61–$0.84 (current) | Trading zone | Reference range |
| $2.09 | 52-week high (one data set) | Distant near-term resistance |
| $14.00 | Analyst price target | Longer-term bull case, reflects pre-pivot coverage |
What to watch tomorrow: The formal shareholder vote on the QUCY name change, expected at an extraordinary general meeting — confirmation of the pivot could be a binary catalyst either way, depending on how the market receives the new strategic direction.
5. Rekor Systems, Inc. (REKR) — ~$0.71 | A Fresh Seven-Year State Contract in Hand
| Metric | Value |
|---|---|
| Recent Price | ~$0.71 |
| 52-Week Range | $0.55 – $3.42 |
| Market Cap | ~$104 million |
Rekor Systems, an AI-powered roadway intelligence company, announced August 11 that it had been selected by the South Carolina Department of Transportation for a statewide contract with a seven-year term — durable, recurring government revenue that distinguishes Rekor from most low-priced names. This adds to Rekor’s existing $16.8 million Oklahoma District Attorneys Council contract. Q2 2026 results also showed a sharply reduced adjusted EBITDA loss, down 78% year-over-year to approximately $1.3 million.
Bull Case vs. Bear Case
Bull case: One community technical analysis flagged a 75-80% estimated probability of REKR reaching $2, citing support-zone technicals, low debt, and a tight roughly 31-million-share float with an estimated 20% short interest — a setup that could fuel a squeeze-driven move.
Bear case: Full-year 2025 losses still totaled $31.46 million against revenue of just $48.45 million, and the company has a history of Nasdaq bid-price compliance concerns tied to trading below $1.
Technical Levels and Forecast
| Level | Type | Note |
|---|---|---|
| $0.55 | 52-week low | Absolute floor |
| $0.65–$0.70 | Support zone | Recent consolidation base |
| $0.71 (current) | Trading zone | Near-term action |
| $1.00 | Psychological resistance | Nasdaq compliance threshold |
| $2.00 | Technical target | Flagged in recent squeeze-setup analysis |
| $3.42 | 52-week high | Full recovery target |
What to watch tomorrow: Any additional state or municipal contract announcements — Rekor’s business model rewards investors who track its government-sales pipeline closely.
6. Antelope Enterprise Holdings Limited (AEHL) — ~$0.84 | A Ceramics Maker Betting Big on Bitcoin
| Metric | Value |
|---|---|
| Recent Price | ~$0.84 |
| Market Cap | ~$11.7 million |
| FY2025 Revenue | $81.1 million (down 17.9% YoY) |
Originally a Chinese ceramics tile manufacturer, Antelope Enterprise has spent 2026 building out a Bitcoin treasury strategy, including a formal cooperation agreement with custody provider BitGo and a $50 million financing facility with Streeterville Capital earmarked for digital-asset accumulation. The company regained Nasdaq listing compliance in March, and management has been actively repurchasing shares, funded partly by realized gains from its digital-asset allocation strategy. The company’s underlying geology also offers exposure to Platinum Group Elements, an additional speculative angle beyond the ceramics and crypto stories.
Bull Case vs. Bear Case
Bull case: The combination of an active buyback program and Bitcoin-treasury exposure gives AEHL two distinct catalysts beyond its legacy ceramics business — a name that can move on crypto sentiment independent of its industrial fundamentals.
Bear case: Fiscal 2025 revenue fell 17.9% year-over-year to $81.1 million, with losses widening 36.1% to $14.35 million — the underlying legacy business remains under real pressure even as the crypto narrative draws attention away from that weakness.
Technical Levels and Forecast
| Level | Type | Note |
|---|---|---|
| $0.48 | 52-week low (post-split adjusted) | Deep floor |
| $0.75 | Support zone | Recent consolidation base |
| $0.84 (current) | Trading zone | Near-term action |
| $1.00 | Psychological resistance | Round-number ceiling |
What to watch tomorrow: Bitcoin’s own price direction — AEHL’s near-term moves are increasingly tied to crypto sentiment rather than its ceramics operations.
7. Genius Group Limited (GNS) — ~$0.18 | An AI Education Play With a Cash Bonus Program Still Live
| Metric | Value |
|---|---|
| Recent Price | ~$0.18 |
| 52-Week Range | $0.15 – $1.28 |
| Sector | AI education / digital banking |
Genius Group has pursued an unusually ambitious dual strategy in 2026: expanding its AI-education platform while deploying capital from an $800 million “AI Treasury” initiative that has included pre-IPO exposure to companies like Anthropic, SpaceX, and OpenAI via the Fundrise Innovation Fund. The company previously ran a Share Loyalty Bonus Program offering cash payments per qualifying share, designed to provide technical price support.
Bull Case vs. Bear Case
Bull case: Unaudited results earlier in the year showed revenue up sharply year-over-year alongside a swing to net operating profit, and the AI Treasury initiative gives shareholders indirect exposure to some of the most sought-after private AI companies in the world.
Bear case: A securities class action has been filed alleging investor harm, and the stock remains just $0.03 above its 52-week low of $0.15 — a sign the market remains skeptical of the broader narrative despite the operating-profit swing.
Technical Levels and Forecast
| Level | Type | Note |
|---|---|---|
| $0.15 | 52-week low | Being tested closely |
| $0.18 (current) | Trading zone | Near-term action |
| $0.30 | Near-term resistance | Recent swing high zone |
| $1.28 | 52-week high | Distant recovery target |
What to watch tomorrow: Any close below $0.15 would represent a genuinely bearish technical breakdown, while continued support at current levels would suggest the loyalty-program mechanism is holding.
8. Milestone Scientific Inc. (MLSS) — ~$0.30–$0.58 | A Medical Device Story Riding Accelerating Revenue Growth
| Metric | Value |
|---|---|
| Recent Range | $0.30 – $0.58 |
| 52-Week Range | $0.22 – $1.39 |
| Analyst Target | $1.00–$1.25 (Buy) |
Milestone Scientific, maker of the CompuFlo pressure-guided injection system used in epidural, neuromodulation, and interventional pain procedures, has posted accelerating revenue growth: preliminary first-half 2026 revenue came in around $5.0 million, up 9% year-over-year, with a more recent quarter showing 21% year-over-year growth — a genuinely encouraging signal for a company this small.
Bull Case vs. Bear Case
Bull case: Accelerating quarter-over-quarter revenue growth and expanding physician adoption support the bullish analyst case toward the $1.00-$1.25 target range, a potential double or more from current levels.
Bear case: The company remains unprofitable with a market cap below $70 million, and continued cash burn makes further dilutive financing a real possibility.
Technical Levels and Forecast
| Level | Type | Note |
|---|---|---|
| $0.22 | 52-week low | Absolute floor |
| $0.30–$0.35 | Support zone | Recent trading range |
| $0.58 | Recent high | Near-term resistance |
| $1.00–$1.25 | Analyst target range | Bull case |
What to watch tomorrow: Sustained double-digit revenue growth through the back half of 2026 would be needed to justify current analyst targets holding.
9. Synergy CHC Corp. (SNYR) — ~$0.20 | A Tiny Float Riding a Fresh Retail Win
| Metric | Value |
|---|---|
| Recent Price | ~$0.20 |
| Shares Outstanding | ~11.25 million |
| Short Interest Change | +27.59% month-over-month |
Synergy CHC, which markets the FOCUSfactor brain-health supplement brand along with Flat Tummy and Hand MD skincare lines, expanded FOCUSfactor’s functional beverage distribution across Canada through Walmart — a meaningful retail shelf-space win for a company of this size, with only about 11.25 million shares outstanding.
Bull Case vs. Bear Case
Bull case: The extremely thin float means even a modest sales inflection from the new Walmart Canada distribution could have an outsized effect on the share price.
Bear case: The stock has fallen more than 90% over the past year, and short interest recently rose 27.59% month-over-month — bearish positioning is actually increasing even as the retail-distribution news should theoretically be a positive catalyst.
Technical Levels and Forecast
| Level | Type | Note |
|---|---|---|
| $0.19 | 52-week low | Being tested |
| $0.20 (current) | Trading zone | Near-term action |
| $0.30 | Near-term resistance | Recent swing level |
| $4.00 | 52-week high | Distant recovery target |
What to watch tomorrow: Same-store sell-through data from the new Canadian distribution channel as the clearest near-term indicator of whether the brand-expansion thesis can overcome building short interest.
10. Nano-X Imaging Ltd. (NNOX) — ~$1.06–$1.08 | A Medical Imaging Story With a Looming Shareholder Vote
| Metric | Value |
|---|---|
| Recent Price | ~$1.06–$1.08 |
| 52-Week Range | $0.73 – $4.88 |
| Average Analyst Target | $5.80 (Strong Buy) |
Nano-X Imaging has faced real balance-sheet turbulence this year — going-concern doubts, a broad impairment review, and an $8 million registered direct offering — even as it continues to sign new commercial deals for its FDA-cleared Nanox.ARC multisource imaging system, including a recent agreement with Howard Technology Solutions. The company has set a September 17, 2026 shareholder meeting to approve a share capital increase, typically a precursor to further dilutive financing.
Bull Case vs. Bear Case
Bull case: The average analyst target of $5.80 implies more than 400% upside, reflecting continued institutional belief in the company’s imaging technology and expanding teleradiology and Health IT revenue streams.
Bear case: Going-concern language, an active impairment review, and a pending share capital increase vote collectively represent a serious balance-sheet risk profile — a name where the fundamental story and financial reality have diverged sharply.
Technical Levels and Forecast
| Level | Type | Note |
|---|---|---|
| $0.73 | 52-week low | Absolute floor |
| $1.00 | Psychological support | Round-number floor |
| $1.06–$1.08 (current) | Trading zone | Near-term action |
| $1.50 | Near-term resistance | Recent swing zone |
| $5.80 | Average analyst target | Longer-term bull case |
What to watch tomorrow: The September 17 shareholder meeting is the single most important date to circle — approval of a share capital increase would likely precede additional dilutive offerings.
Sector Sentiment Snapshot
This list splits into three distinct stories: crypto-treasury pivots (Pineapple Financial, Antelope Enterprise) that now trade partly on digital-asset sentiment rather than their legacy businesses; genuine operational turnarounds with recurring revenue (Rekor Systems, Milestone Scientific, SurgePays); and speculative, thin-float names (Genius Group, Synergy CHC, Mainz Biomed/Quantum Cyber) where a single news event could produce an outsized move given how few shares are actually available to trade. Dilution risk remains elevated across nearly every name on this list — a pattern worth treating as a near-certainty rather than a tail risk at this price tier.
Follow TNN for daily stock market news and financial news today.
Disclaimer: This publication is entirely for informational and journalistic purposes and does not constitute formal financial, investment, or legal advice. All market investments carry inherent risks of capital loss, and stocks trading under $3 carry substantially elevated risk, including wide bid/ask spreads, thin liquidity, dilution, and delisting risk. Support and resistance levels cited are technical analysis estimates based on historical price data and do not guarantee future price behaviour. Always complete independent due diligence prior to executing equity trades.
About The Author
